Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335777 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL8886861 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL767076 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL12070284 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL144832 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL7087412 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL6166 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| SCHEMBL13363641 | 0.83 | CTSK (0.51) | CTSKCTSSPPARAPPARGATM | |
| Water SCHEMBL7774670 | 0.82 | CTSK (0.53) | CTSKCTSSPPARAPPARGATM | |
| Water SCHEMBL8011422 | 0.82 | CTSK (0.53) | CTSKCTSSPPARAPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO | 2005-09-22 | — | — | US | disclosed |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | TOCQUE BRUNO (FR) | 2004-07-01 | — | — | US | disclosed |
| US-20030083497-A1 | Taxoids, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA, S.A. | 2003-05-01 | — | — | US | disclosed |
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TOCQUE BRUNO (FR) | 2001-09-13 | — | — | US | disclosed |
| US-6262032-B1 | WHEREIN THE ADENOVIRAL VECTOR AND THE TAXOID COMPOUND ARE BROUGHT INTO CONTACT WITH THE CELL SIMULTANEOUSLY. | AVENTIS PHARMA S.A. (FR) | 2001-07-17 | — | — | US | disclosed |
| US-5670536-A | Pharmaceutical composition based on taxoids | RHONE-POULENC RORER S.A. (FR) | 1997-09-23 | — | — | US | disclosed |
| US-5606083-A | Process for the preparation of taxane derivatives, new derivatives thus obtained and the compositions which contain them | RHONE-POULENC RORER S.A. (FR) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083497-A1 | Taxoids, their preparation and pharmaceutical compositions containing them | TBXA2R, CBR1, CBR3 | CTSK 1098/4885CTSS 2261/4885ABCB1 4/4885 |
| US-20010021395-A1 | Method for destroying hyperproliferative cells by combined p53 and taxoid treatment | TP53, HRAS, MYC | CTSK 1348/4885CTSS 2004/4885ABCB1 2765/4885 |
| US-20050209177-A9 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CTSK 3043/4885CTSS 3468/4885ABCB1 3347/4885 |
| US-20040127437-A1 | Combined therapeutical treatment of hyperproliferative diseases | HRAS, MYC, TP53 | CTSK 3043/4885CTSS 3468/4885ABCB1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.